Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Funk

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2012
Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studiesAgnès Poirier, Sara Belli, Christoph Funk, et al.
Journal of Medicinal Chemistry|March 5, 2004
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidinePeter Angehrn, Stefan Buchmann, Christoph Funk, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 29, 2014
In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYPMizuki Yamane, Kosuke Kawashima, Koji Yamaguchi, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 23, 2017
Application of Imaging Techniques to Cases of Drug-Induced Crystal Nephropathy in Preclinical StudiesBarbara Lenz, Andreas Brink, Monira Siam, et al.
Science Translational Medicine|June 21, 2019
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeuticsChristopher W McAleer, Christopher J Long, Daniel Elbrecht, et al.
The AAPS Journal|January 5, 2017
Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects ModelingNicole A Kratochwil, Christophe Meille, Stephen Fowler, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2018
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory GuidanceSimone Schadt, Bojan Bister, Swapan K Chowdhury, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 11, 2015
Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depressionLothar Lindemann, Richard H Porter, Sebastian H Scharf, et al.
Journal of Medicinal Chemistry|January 8, 2015
Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseasesGeorg Jaeschke, Sabine Kolczewski, Will Spooren, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2012
Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studiesAgnès Poirier, Sara Belli, Christoph Funk, et al.
Journal of Medicinal Chemistry|March 5, 2004
New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidinePeter Angehrn, Stefan Buchmann, Christoph Funk, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 29, 2014
In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYPMizuki Yamane, Kosuke Kawashima, Koji Yamaguchi, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 23, 2017
Application of Imaging Techniques to Cases of Drug-Induced Crystal Nephropathy in Preclinical StudiesBarbara Lenz, Andreas Brink, Monira Siam, et al.
Science Translational Medicine|June 21, 2019
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeuticsChristopher W McAleer, Christopher J Long, Daniel Elbrecht, et al.
The AAPS Journal|January 5, 2017
Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects ModelingNicole A Kratochwil, Christophe Meille, Stephen Fowler, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2018
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory GuidanceSimone Schadt, Bojan Bister, Swapan K Chowdhury, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 11, 2015
Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depressionLothar Lindemann, Richard H Porter, Sebastian H Scharf, et al.
Journal of Medicinal Chemistry|January 8, 2015
Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseasesGeorg Jaeschke, Sabine Kolczewski, Will Spooren, et al.
Pageof 5